Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB

Thorax

Volumn 65, Issue 7, 2010, Pages 582-587

  Aspler, Anne ^a,b   Long, Richard ^b   Trajman, Anete ^c   Dion, Marie Josée ^a   Khan, Kamran ^d   Schwartzman, Kevin ^a   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c GAMA FILHO UNIVERSITY   (Brazil)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ERUPTION; DRUG WITHDRAWAL; FINANCIAL MANAGEMENT; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MONOTHERAPY; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ADULT; BRAZIL; CANADA; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; DRUG COST; ECONOMICS; HEALTH SERVICE; MULTICENTER STUDY; SAUDI ARABIA; STATISTICS; UTILIZATION REVIEW;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; BRAZIL; CANADA; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; RIFAMPIN; SAUDI ARABIA;

EID: 77955293373     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.125054     Document Type: Article

References (35)

1. World Health Organization. Global tuberculosis control. surveillance, planning, financing: 2008. (WHO/HTM/TB/2006.362). Geneva: World Health Organization, 2008.
2. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47.
3. Long RL, Ellis E. Canadian tuberculosis standards. 6th edn. Toronto: Canadian Lung Association, Public Health Agency of Canada, Tuberculosis Prevention and Control, 2007.
4. Horsburgh CR, Goldberg S, Bethel J, et al. Studies Consortium. Low latent tuberculosis infection treatment completion with the 9 month INH regimen. Am J Respir Crit Care Med 2007;175:A24.
5. Sterling TR, Bethel J, Goldberg S, et al. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006;173:927-31.
6. McElroy PD, Ijaz K, Lambert LA, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005;41:1125-33.
7. Comstock GM. How much isoniazid is needed for prevention of tuberculosis in immunocompetent adults. Int J Tuberc Lung Dis 1999;3:847-50.
8. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med 2002;347:1860-6.
9. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months rifampin or 9 months isoniazid as therapy for latent TB infection: results of a randomised trial. Ann Intern Med 2008;149:689-97.
10. Page KR, Sifakis F, Montes de OR, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006;166:1863-70.
11. Lardizabal A, Passannante M, Kojakali F, et al. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006;130:1712-17.
12. Global Drug Facility. First-line tuberculosis drugs and formulations currently supplied/to be supplied by the global TB drug facility. World Health Organization, 2003. http://stoptb.org/GDF/drugsupply/drugs.available.html (accessed 31 Jul 2008).
13. Bank of Canada. Exchange rates 2007, 2007. http://www.bank-banque-canada. ca/pdf/nraa04.pdf (accessed 23 Jul 2007).
14. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd edn. New York: Oxford University Press, 1997.
15. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
16. Dawson-Saunders B, Trapp RG. Basic and clinical biostatistics. Norwalk: Appleton and Lange, 1990.
17. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976;19:1-63.
18. Sutherland I. The evolution of clinical tuberculosis in adolescents. Tubercle 1966;47:308.
19. Hong Kong Chest Service Tuberculosis Research Centre MBMRC. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
20. Haley CA, Stephan S, Vossel LF, et al. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Int J Tuberc Lung Dis 2008;12:160-7.
21. Nolan CM, Goldberg SV, Buskin SE. Hepatoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-18.
22. Sorresso D, Mehta JB, Harvill LM, et al. Underutilization of isoniazid chemoprophylaxis in tuberculosis contacts 50 years of age and older: a prospective study. Chest 1995;108:706-11.
23. Polesky A, Farber HW, Gottlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996;154:1473-7.
24. Villarino ME, Ridzon R, Weismuller PC, et al. Rifampin preventive therapy for tuberculosis infection. Am J Respir Crit Care Med 1997;155:1735-1.
25. Gao XF, Wang L, Liu GJ, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis 2006;10:1080-90.
26. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-7.
27. Jasmer RM, Daley CL. Rifampin and pyrazinamide for treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2003;167:809-12.
28. Omerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78:169-71.
29. Center for Disease Control and Prevention. Reported tuberculosis in the United States, 2006. Atlanta, GA: US Department of Health and Human Services, Public Health Service, 2007.
30. Ellis E, Medaglia A, Phypers M, et al. Tuberculosis: drug resistance in Canada, 2006: reported susceptibility results of the Canadian tuberculosis laboratory surveillance system. Health Canada, 2007.
31. World Health Organization. Anti-tuberculosis drug resistance in the world report no.4. WHO/HTM/TB/2008. 2008. Geneva: World Health Organization; http://whqlibdoc.who.int/publications/2008.
32. Khan K, Muennig P, Behta M, et al. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347:1850-9.
33. Balcells ME. INH resistance after INH therapy. Emerg Infect Dis 2006;12:744-9.
34. Caminero JA. Treatment of multidrug resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006;10:829-37.
35. Menzies D, Lewis M, Oxlade O. Costs for tuberculosis care in Canada. Can J Public Health 2008;99:391-6.